Inventurus Knowledge Solutions Limited has released the audio recording of its earnings conference call for the first quarter of fiscal year 2026-27 (Q1 FY2026-27). The recording is now accessible on the company's investor relations website, providing stakeholders with direct access to management's commentary on the quarterly performance. This disclosure follows the company's earlier communication dated July 31, 2026, regarding the results announcement.

The earnings call was conducted on Thursday, August 6, 2026. By making the audio available, Inventurus Knowledge Solutions ensures transparency and allows investors to review the detailed discussion surrounding the financial outcomes for the period. The move aligns with standard market practices for listed entities in India to provide comprehensive post-result analysis.

Regulatory Compliance

The release of the audio recording is a mandatory compliance step under the Securities and Exchange Board of India (SEBI) regulations. Specifically, the action is taken pursuant to Regulation 30 and Regulation 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. These regulations require listed entities to disseminate material information promptly and ensure that records of significant disclosures, such as earnings calls, are preserved and made available.

Accessing the Recording

Investors and analysts can access the audio file directly via the link provided on the company's official website. The recording captures the entire session, including questions from analysts and responses from company management. This resource serves as a primary source for understanding the strategic context behind the reported numbers for Q1 FY2026-27.

The compliance officer, Sameer Chavan, signed off on the communication to the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE). The notice was issued from the company's registered office in Navi Mumbai, Maharashtra, reinforcing the formal nature of the disclosure.

Inventurus Knowledge Solutions Limited has announced that its wholly owned subsidiary, Inventurus Knowledge Solutions Inc ("IKS Inc"), has entered into a Stock Purchase Agreement ("SPA") for the sale of its equity stake in Abridge AI Inc. The agreement, dated August 05, 2026, sees IKS Inc selling 54,055 Series A-1 Preferred Shares to Alpha Square Group Fund IV, LP (the "Purchaser") for an aggregate consideration of USD 10,000,175. This transaction represents a partial divestment aimed at monetizing the subsidiary's holdings in the artificial intelligence entity.

The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"). The company also referenced compliance with SEBI Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026. Abridge AI Inc acted as a confirming party to the agreement. The transaction is not classified as a related party transaction, as none of the parties are related to the promoters or promoter group of Inventurus Knowledge Solutions Limited.

Transaction Details

The key terms of the Stock Purchase Agreement are outlined below:

The primary purpose of entering into this agreement is the monetization or partial divestment of the Series A-1 Preferred Shares held by IKS Inc in Abridge AI Inc. The filing confirms that there is no shareholding by Inventurus Knowledge Solutions Limited in the entity with whom the agreement was executed, nor are there any special rights such as the right to appoint directors or restrict changes in capital structure associated with this specific transfer.

Regulatory Compliance

The disclosure was submitted to both BSE Limited and the National Stock Exchange of India Limited on August 06, 2026. Sameer S Chavan, Company Secretary and Compliance Officer of Inventurus Knowledge Solutions Limited, signed the disclosure. The company stated that the transaction falls outside the scope of related party transactions as defined under the SEBI LODR Regulations. No other disclosures regarding nominee appointments, potential conflicts of interest, or amendments to existing agreements were reported in connection with this SPA.